Atia Vision's OmniVu IOL Shows Promising 2-Year Results for Presbyopia and Cataract Treatment
核心洞察
Atia Vision (搜索)'s OmniVu (搜索) modular IOL system demonstrates excellent safety and refractive stability over 24 months, maintaining stability within a 1/2 diopter.
The dual-optic design provides a continuous range of vision, achieving 20/16 binocular distance acuity, 20/20 intermediate, and J1 near vision.
The lens system maintains the natural capsule, potentially promoting effective lens position and monofocal-like contrast sensitivity.
At the American Academy of Ophthalmology meeting in Chicago, George O. Waring, IV, MD, presented compelling 24-month clinical feasibility trial outcomes for Atia Vision (搜索)'s OmniVu (搜索) modular intraocular lens (IOL) system, showcasing its potential for treating presbyopia (搜索) and cataract (搜索). The data indicates excellent safety and efficacy, with stable refractive outcomes and a continuous range of vision.
The OmniVu (搜索) system is a two-piece modular lens featuring an exchangeable anterior optic and a fluid-filled, shape-changing base designed to provide accommodation. This design aims to mimic the natural lens function, maintaining the natural capsule in a capsule-filling manner. According to Dr. Waring, this approach may promote effective lens position over time, contributing to the observed stability.
"These lenses are maintaining stability, refractive stability, over 24 months within a 1/2 diopter," Dr. Waring stated. He also highlighted the uncorrected binocular visual acuity outcomes, which were 20/16 for distance, 20/20 for intermediate, and J1 for near vision. The system provided over four and a half diopters into focus at the 20/32 level, offering a natural range of vision with excellent quality.
Contrast sensitivity results were comparable to monofocal lenses, suggesting that the OmniVu (搜索) system does not compromise visual quality. The modular design also allows for future adjustability and potential integration with drug delivery or virtual reality technologies, expanding its long-term utility.
Dr. Waring expressed optimism about the technology's future, emphasizing its potential to provide a more physiologic solution for patients with presbyopia (搜索) and cataracts. The 2-year data supports the lens's stability, efficacy, and safety, marking a significant step forward in accommodating IOL technology.